Biocon inks deal with Amgen to market Bosaya & Aukelso biosimilars (Prolia & Xgeva copies) in the US from Oct 2025.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s ...

Biotechnology firm Biocon on Wednesday said its unit has inked a settlement and license agreement with Amgen Inc., paving the ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...

India-based Biocon’s biosimilars subsidiary has reached a settlement and license agreement with Amgen that clears the path ...

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

Neurons selective to running trajectories in the rat anterior cingulate cortex are reactivated during observation and interact with hippocampal replay to guide subsequent spatial navigation.

Individual retinal ganglion cells are singularly activated in the living primate retina via an adaptive optics scanning light ophthalmoscope.

Find out how single-use optical technology enables accurate, non-invasive cell monitoring in rocking motion bioreactor setups ...

Digitalization and automation enhance aseptic processing by improving speed, repeatability, and quality, with recipe-driven ...